Full Press Release Details
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that Dr. Helen Torley , President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences.
Details on the Company's participation are as follows:
| Event: | 2025 Wells Fargo Healthcare Conference | |||
| Format: | Fireside Chat and 1x1 Meetings | |||
| Presentation Date: | Thursday, September 4, 2025 | |||
| Presentation Time: | 10:30am PT / 1:30pm ET | |||
| Location: | Boston, MA |
| Event: | Morgan Stanley 23 rd Annual Global Healthcare Conference | |||
| Format: | Fireside Chat and 1x1 Meetings | |||
| Date: | Monday, September 8, 2025 | |||
| Presentation Time: | 4:45am PT / 7:45am ET | |||
| Location: | New York, NY | |||
| Event: | H.C. Wainwright 27 th Annual Global Investment Conference | |||
| Format: | 1x1 Meetings | |||
| Date: | Tuesday, September 9, 2025 | |||
| Location: | New York, NY |
A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected]
Sydney Charlton Teneo 917-972-8407 [email protected]
SOURCE Halozyme Therapeutics, Inc.